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Background: Systemic juvenile idiopathic arthritis (sJIA) is commonly considered an autoinflammatory disease.
However, sJIA patients may develop aggressive arthritis without systemic inflammation later in the disease,
resembling an autoimmune phenotype similar to other subtypes of JIA. The objective of this study was to
determine whether antinuclear antibodies (ANA) and rheumatoid factor (RF) will develop in patients with sJIA over
the course of the disease.
Findings: A single center sample of sJIA patients with follow-up of more than one year was obtained. A retrospective
chart survey was used to extract demographic and clinical data as well as presence and titers of ANA and RF at
diagnosis and during follow-up. 32 patients were included in the study, with a median age of 4.2 years and median
follow-up of 6.0 years. 8/32 patients had ANA titers ≥ 1:80 at diagnosis, with 22/32 patients showing rising ANA titers
with titers ≥ 1:80 at last follow-up (p =0.001). 10/32 patients had a positive RF at least once during follow-up, compared
to 0/32 at diagnosis (p = 0.001). In 5/10 patients, positive RF was documented at least twice, more than twelve weeks
apart. Patients treated with TNF antagonists were not significantly more likely to develop positive ANA titers (p = 0.425)
or positive RF (p = 0.703).
Conclusions: Patients with sJIA developed increased ANA titers and positive RF over the course of the disease,
independent of treatment with TNF antagonists. This might point towards an autoimmune, rather than an
autoinflammatory phenotype later in the course of sJIA.
Keywords: Juvenile systemic arthritis, Juvenile idiopathic arthritis, Antinuclear antibodies, Rheumatoid
factor - autoimmunityFindings
Introduction
Systemic juvenile idiopathic arthritis (sJIA) is a disease
characterized by marked systemic inflammation and a
high rate of severe and potentially life-threatening ma-
nifestations. While categorized as a subtype of juvenile
idiopathic arthritis (JIA) according to the ILAR-criteria,
sJIA is currently considered to represent an autoin-
flammatory rather than an autoimmune syndrome [1-3].* Correspondence: huegle.boris@rheuma-kinderklinik.de
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normalities of the innate immune system with hallmark
findings of seemingly unprovoked inflammation, in con-
trast to autoimmune conditions caused by autoreactive T
or B lymphocytes and autoantibodies. This might be an
oversimplification, since features of both autoinflamma-
tion and autoimmunity are typically present in most con-
ditions; hence, a classification of disorders along an axis
between autoinflammation and autoimmunity has been
proposed [2,4].
Although in sJIA, systemic inflammation tends to de-
crease over time in most patients, approximately half of
sJIA patients can be expected to develop an aggressivetd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Dot dispersion plot of antinuclear antibodies titers at
diagnosis and at last follow-up in patients with systemic juvenile
idiopathic arthritis (n = 32).
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type of chronic polyarthritis similar to that observed in
other forms of JIA in which autoimmunity appears to
play an important role.
The objective of this study was to determine frequen-
cies of ANA and RF as circumstantial markers for auto-
immunity in patients with sJIA over the course of the
disease.
Methods
Patient sera and clinical data were acquired from the
AID-Net database (http://www.aid-register.de), a German
registry and biobank that prospectively collects informa-
tion and biomaterials of patients with autoinflammatory
syndromes including periodic fevers syndromes and sJIA
[6]. A single center sample of all patients with sJIA at the
German Center for Pediatric and Adolescent Rheumato-
logy was screened between January 2010 and July 2012,
and all sJIA patients with a follow-up of more than one
year were included. A retrospective chart survey was used
to extract demographic data, clinical course including to-
tal joint count and treatment as well as presence and titers
of antinuclear antibodies (ANA) and rheumatoid factor
(RF) at beginning and during follow-up. All ANA and RF
studies were performed in a single laboratory to ensure
comparability, and the laboratory methods were used con-
sistently during the follow-up period. ANA titers were de-
termined using the HEp-2000 fluorescent ANA-Ro test
system (Immuno Concepts, Sacramento, USA), and rheu-
matoid factors were determined using the Rheuatoid
Factors II test kit with a cobas c 311 analyzer (Roche
Diagnostics GmbH, Mannheim, Germany). Analysis was
performed using descriptive statistics, Student’s T-Test/
Fischer’s Exact test, one-way ANOVA (ANA-positive,
ANA-negative patients and ANA-converted patients),
and Spearman’s correlation (ANA-titers and total active
joint count). Statistical analysis was performed with SPSS
version 21.0 (SPSS Inc., Chicago, USA).
Results
32 patients were included in the study (20 of these fe-
male), with a median age at diagnosis of 4.2 years (range
0.5 – 11.4 years). The median follow-up was 6.0 years
(range 1.1 – 17.3 years). During the course of disease,
96.8% were treated with disease-modifying antirheumatic
drugs (of those: methotrexate 100%, azathioprine 52% and
cyclosporine A 48%), 65.6% with any TNF antagonist (of
those: etanercept 100%, infliximab 14% and adalimumab
29%), 65.6% with anti-interleukin(IL)-1 antagonists and
15.6% with anti-IL-6 antagonists. 8/32 patients had ANA
titers ≥ 1:80 at diagnosis, with 22/32 patients showing a
titer of ≥ 1:80 at last follow-up (p =0.001) (Figure 1). There
was no difference according to age at diagnosis (p =
0.949), length of follow-up (p = 0.197), maximum jointcount at any time (p = 0.348) or total joint count at last
follow-up (p = 0.314) among persistently ANA-negative,
persistently ANA-positive and ANA-seroconverted pa-
tients. Using measures at 463 time points, there was no
correlation between ANA titers and total active joint
count (r = 0.180, p = 0.703). During follow-up, 10/32 pa-
tients had a positive RF at least once, compared to 0/32 at
diagnosis (p = 0.001). In five of these patients, positive
RF were documented at least twice, more than twelve
weeks apart. Patients treated with TNF antagonists were
not significantly more likely to develop a positive ANA
(p = 0.425) or positive RF (p = 0.703).
Discussion
This retrospective, descriptive single-center study shows
an increasing frequency of positive ANA and RF titers
over time in patients with sJIA. In earlier studies, various
types of autoantibodies, including ANA and RF, have
been found in up to one third of patients with sJIA
[7-10]. However, these studies did not differentiate be-
tween varying stages of the disease. While ANA are found
in healthy children and tend to increase with age, the fre-
quencies of autoantibodies demonstrated in our study are
certainly beyond those found in normal controls [11,12].
A correlation between ANA titers and arthritis could not
be demonstrated. While TNF blockade can lead to devel-
opment of ANA, our analysis shows that this is most likely
not a factor in our patient population [13].
As has been previously observed, patients with sJIA
can be divided into three clinical phenotypes, with either
mono- or polyphasic course or persistent disease [5]. The
clinical symptoms tend to change over time. Most patients
with persistent disease show no systemic signs at 6 months
after diagnosis but instead exhibit a particularly severe
progressive polyarthritis, often involving the hip and
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the inflamed joints of patients with sJIA are poorly under-
stood. In other forms of JIA (e.g. oligo-, poly- and spondy-
loarthritis) both indicators of innate immunity, such as
elevated myeloid-related proteins (MRP) 8 and 14 pro-
duced by neutrophils and infiltration by neutrophils,
monocytes and macrophages, and indicators of adaptive
immunity, such as prominent CD4 lymphocyte infiltra-
tion, are found directly in the synovium and synovial fluid
[14,15]. To our knowledge, such detailed data are not
available for patients with sJIA, and the reason for the par-
ticularly aggressive polyarthritis remains enigmatic.
The prodromal, systemic phase of sJIA appears to corre-
late well with a massive activation of the innate immune
system, as indicated e.g. by PBMC gene expression studies
showing marked upregulation and/or overrepresentation
of innate immune signaling pathways, downregulation of
adaptive immunity signaling pathways, and extremely ele-
vated MRP8/14 levels [16,17]. Taking into account the
clinical picture, the lack of female preponderance, the lack
of HLA class II associations, the general lack of autoanti-
bodies in this disease phase and an excellent response to
IL-1 and IL-6 blockade, sJIA may well be regarded as a
‘pure’ autoinflammatory syndrome. This leads to the ques-
tion: How and why is there, in a substantial proportion of
patients, a transition to an aggressive polyarthritis, often
with cessation of the extreme systemic inflammation ini-
tially observed? The presence of increasing autoantibody
titers demonstrated here supports the hypothesis that
the initial inflammatory phenotype of sJIA might in-
duce B- and T-cell mediated autoimmunity later in the
disease, for example via downstream activation of antigen
presentation. Figure 2 illustrates this postulated mechanismFigure 2 Concept schematic of the different disease courses of systemi
two phases of persistent disease course, with initially predominant syst
disease course.of a two-phased disease course, with initial systemic disease
driven by autoinflammatory processes, and ongoing ar-
thritis caused by autoimmunity. Whether or not this
observation is pathogenically relevant or merely an epi-
phenomenon representative of nonspecific polyclonal acti-
vation is unclear and cannot be answered by this study.
An additional argument for a shift in pathogenesis is
the observation that in a substantial proportion of sJIA
patients anti IL-1 treatment does not control the arth-
ritis, or the response to treatment with anti-IL1 agents
decreases over time [18-20]. On the other hand, it has
been hypothesized that treatment with IL-1 antagonists
in the early (i.e. predominantly autoinflammatory) phase
might even prevent transition into a course character-
ized by refractory polyarthritis [21]. Blocking the IL-1
pathway might therefore have a function in suppressing
the transition to persistent B- and T-cell activation.
The assumed transition from an autoinflammatory to
an autoimmune phenotype should be accompanied by a
marked switch in the types of expressed genes, from a
pattern with predominantly innate immune pathway ac-
tivation towards a more T-cell driven picture. Gene ex-
pression profiles in peripheral blood mononuclear cells
(PBMC) of new onset sJIA show up-regulation of genes
from the innate, and down-regulation of genes from the
adaptive immune system [22]. In particular, compared to
other subtypes, new-onset sJIA shows down-regulation
of natural killer cell, T cell, and antigen-presentation
pathways [16]. Clustering of expressed genes can differ-
entiate between patients according to active and inactive
disease, independent of their medications [23]. Similarly,
cluster analysis can distinguish between patients with
high and low ferritin levels, corresponding to the level ofc juvenile idiopathic arthritis. The lower curve shows the postulated
emic disease and development of chronic polyarthritis later in the
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pression analysis has been limited to either new-onset
sJIA or patients in remission. It would be interesting to
see if sJIA patients with arthritis and no systemic fea-
tures, later in the disease course, show a gene expression
profile closer to patients with polyarticular JIA, i.e. ele-
vated expression of monocyte markers and transforming
growth factor β-inducible genes [25].
Strengths of our study include that all consecutive pa-
tients within a single center were included in this study,
thus representing a rather homogeneous patient popula-
tion. Weaknesses of our single-center study include its
retrospective nature, the lack of precise identification of
the progressive polyarthritis subtype reported above, and
the lack of measuring other, non-specific biomarkers of
chronic immune activation (e.g. erythrocyte sedimenta-
tion rate or IgG levels); since our center is a tertiary re-
ferral center, there may have been a bias towards more
serious cases. It should be noted that many of the results
in this study are based on single instances of elevated
test results. Both ANA and RF can be unspecifically ele-
vated due to infections and other causes of immune acti-
vation, introducing possible causes of error. Especially
with rheumatoid factor, ILAR guidelines recommend the
determination of two elevated titers 3 months apart,
which could not be confirmed in each patient in this
study [3]. However, individual patients in our study tren-
ded toward increasing titers over time. ANA titers might
also be affected by medications beyond TNF inhibitors, as
well as immunosuppression induced by these medications.
The retrospective nature of this study, as well as the var-
iety of medications used in this study, precluded any fur-
ther analysis.Conclusion
In summary, this study demonstrates increasing serum
autoantibody titers over time in a proportion of patients
with sJIA, indicating the potential role of lymphocyte ac-
tivation and autoimmune processes in this primarily
autoinflammatory condition. It remains unclear if this is
indeed of pathogenic relevance, or merely an epipheno-
menon. Further studies, especially longitudinal gene ex-
pression studies in target tissues, such as synovium or
synovial fluid, in patients with the chronic polyarthritis
phenotype of sJIA, will be necessary to elucidate this
phenomenon.
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